Countervail Corporation

Medtech · Private

Point-of-care diagnostic device for measuring acetylcholinesterase and butylcholinesterase enzyme activity to detect organophosphate exposure

countervailcorp.com →
Grants
$855K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$11M
1 award · Health and Human S
#65 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Countervail Corporation"nerve Agent Countermeasure For Sub-lethal Exposures"$10,961,044
Federal grantDepartment of Health and Human Services · Phase II · Definitive Studies For Use Of Galantamine As A Pre-Treatment Countermeasure Again$630,123
Federal grantDepartment of Health and Human Services · Phase I · Rapid Baseline Free Organophosphate Exposure Diagnostic Test$225,225
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
62ALTEC, INC$12M—
63ProteinSimple$11M—
64TANGEN BIOSCIENCES, INC.$11M$20M
65Countervail Corporation$11M—
66BLACKROCK MICROSYSTEMS, INC$11M$12M
67QUANTITATIVE BIOSCIENCES, INC.$11M—
68Biomeme Inc$11M$5.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.